Mapping the clinical trial landscape of multiple primary lung cancer in the era of precision oncology: persistent exclusion and design limitations hamper evidence-based treatment development
{{output}}
Multiple primary lung cancer (MPLC) is increasingly recognized for its clinical and biological significance, yet it remains strikingly underrepresented in clinical trials. We systematically analyzed 8,212 lung cancer trials registered between 2015 and 2024 acr... ...
